These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30191914)

  • 1. CANTOS - is selective targeting of inflammation in atherosclerosis enough?
    Misra DP; Agarwal V
    J R Coll Physicians Edinb; 2018 Sep; 48(3):246-247. PubMed ID: 30191914
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials.
    Ridker PM
    J Intern Med; 2019 May; 285(5):503-509. PubMed ID: 30472762
    [No Abstract]   [Full Text] [Related]  

  • 3. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From clinical observations to molecular mechanisms and back to patients: the successful circuit of the CANTOS study.
    Lembo G
    Cardiovasc Res; 2018 Jan; 114(1):e3-e5. PubMed ID: 29293914
    [No Abstract]   [Full Text] [Related]  

  • 5. Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications.
    Ridker PM
    Circulation; 2018 Apr; 137(17):1763-1766. PubMed ID: 29273581
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and Atherosclerosis: The End of a Controversy.
    Hansson GK
    Circulation; 2017 Nov; 136(20):1875-1877. PubMed ID: 28916641
    [No Abstract]   [Full Text] [Related]  

  • 9. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation and atherosclerosis: fulfilling Koch's postulates.
    Jialal I; Vikram NK
    Ther Adv Cardiovasc Dis; 2018 Jan; 12(1):5-6. PubMed ID: 29187060
    [No Abstract]   [Full Text] [Related]  

  • 11. The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology.
    Baylis RA; Gomez D; Mallat Z; Pasterkamp G; Owens GK
    Arterioscler Thromb Vasc Biol; 2017 Nov; 37(11):e174-e177. PubMed ID: 28970294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for cardiovascular disease.
    Lutgens E; Atzler D; Döring Y; Duchene J; Steffens S; Weber C
    Eur Heart J; 2019 Dec; 40(48):3937-3946. PubMed ID: 31121017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study.
    Krause K; Mahamed A; Weller K; Metz M; Zuberbier T; Maurer M
    J Allergy Clin Immunol; 2013 Sep; 132(3):751-754.e5. PubMed ID: 23711544
    [No Abstract]   [Full Text] [Related]  

  • 14. [Inflammation and atherosclerosis – last piece of the puzzle has fallen into place].
    Jonasson L; Hansson G
    Lakartidningen; 2017 Oct; 114():. PubMed ID: 29292899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?
    Ridker PM
    Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469
    [No Abstract]   [Full Text] [Related]  

  • 16. Critical roles of inflammation in atherosclerosis.
    Moriya J
    J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.
    Libby P
    J Am Coll Cardiol; 2017 Oct; 70(18):2278-2289. PubMed ID: 29073957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
    Ridker PM
    Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102
    [No Abstract]   [Full Text] [Related]  

  • 19. Blocking inflammation: a new arsenal against atherosclerosis.
    Ruiz-Canela M; Martínez-González MA
    Endocrinol Diabetes Nutr; 2017 Dec; 64(10):515-516. PubMed ID: 29146173
    [No Abstract]   [Full Text] [Related]  

  • 20. The Emerging Role of Inflammation in Cardiovascular Disease.
    Martinez BK; White CM
    Ann Pharmacother; 2018 Aug; 52(8):801-809. PubMed ID: 29557210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.